Efficacy and safety of endocrine therapy after mastectomy in patients with hormone receptor positive breast ductal carcinoma in situ: Retrospective cohort study
eLife · 2023
DOI: 10.7554/elife.83045 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift eLife, 2023. Verfasst von Nan Niu und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, China. Hauptthemen laut MEDLINE: Carcinoma, Intraductal, Noninfiltrating, Breast Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Outstanding Young Scholars of Liaoning Province, Outstanding Scientific Fund of Shengjing Hospital.
Abstract (Originalsprache)
Background
More than half of Chinese patients with hormone receptor positive (HR+) ductal carcinoma in situ (DCIS) are treated with mastectomy, and usually subjected to postoperative endocrine therapy (ET). Given that long-term ET can cause severe adverse effects it is important to determine the beneficial effect and safety of post-mastectomy ET on the disease-free survival (DFS) and adverse events in patients with HR+ DCIS.
Methods
To explore beneficial effect and safety of post-mastectomy ET in patients with HR+ DCIS, we performed a multicenter, population-based study. This retrospective study analyzed the DFS and adverse events in 1037 HR+ DCIS Chinese patients with or without post-mastectomy ET from eight breast centers between 2006 and 2016. The median follow-up time period was 86 months.
Results
There were 791 DCIS patients receiving ET (ET group). Those patients were followed up for a median of 86 months (range, 60–177 months). There were 23 cases with tumor recurrence or distant metastasis. There were similar 5-year DFS rates and DFS between the ET and non-ET groups, even for those with high-risk factors. Conversely, 37.04% of patients suffered from adverse events after ET, which were significantly higher than those in the non-ET group.
Conclusions
ET after mastectomy did not benefit patients with HR+ DCIS for their DFS, rather increased adverse events in those patients. Therefore, ET after mastectomy may not be recommended for patients with HR+ DCIS, even for those with high-risk factors, such as multifocal, microinvasive, and higher T stage. Funding: This study was supported by grants from Outstanding Scientific Fund of Shengjing Hospital (201803) and Outstanding Young Scholars of Liaoning Province (2019-YQ-10).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, China.
- Department of Nursing, Shengjing Hospital of China Medical University, Shenyang, China.
- Department of Breast Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Beijing, China.
- Department of Breast Surgery, the First Hospital of Jilin University, Changchun, China.
- Department of Breast Surgery, Liaoning Cancer Hospital and Institute, Shenyang, China.
- Department of Breast Surgery, Cancer Hospital of Harbin Medical University, Harbin, China.
ORCID-Profile: Nan Niu, Xinbo Qiao, Caigang Liu
Förderung
- Outstanding Young Scholars of Liaoning Province
- Outstanding Scientific Fund of Shengjing Hospital
Zitieren
APA
Niu, N., Zhang, Y., Bai, Y., Wang, X., Yan, S., Song, D., Xu, H., Liu, T., Hua, B., Zhang, Y., Liu, J., Qiao, X., Liu, J., Zheng, X., Cao, H., & Liu, C. (2023). Efficacy and safety of endocrine therapy after mastectomy in patients with hormone receptor positive breast ductal carcinoma in situ: Retrospective cohort study. eLife. https://doi.org/10.7554/elife.83045
Vancouver
Niu N, Zhang Y, Bai Y, Wang X, Yan S, Song D, et al. Efficacy and safety of endocrine therapy after mastectomy in patients with hormone receptor positive breast ductal carcinoma in situ: Retrospective cohort study. eLife. 2023. doi:10.7554/elife.83045
BibTeX
@article{Niu2023,
author = {Niu, Nan and Zhang, Yinan and Bai, Yang and Wang, Xin and Yan, Shunchao and Song, Dong and Xu, Hong and Liu, Tong and Hua, Bin and Zhang, Yingchao and Liu, Jinchi and Qiao, Xinbo and Liu, Jiaxiang and Zheng, Xinyu and Cao, Hongyi and Liu, Caigang},
title = {Efficacy and safety of endocrine therapy after mastectomy in patients with hormone receptor positive breast ductal carcinoma in situ: Retrospective cohort study},
journal = {eLife},
year = {2023},
doi = {10.7554/elife.83045}
}
EUVIMED